<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902019000300282</article-id>
<article-id pub-id-type="doi">10.29262/ram.v66i3.401</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Omalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A serie of cases]]></article-title>
<article-title xml:lang="es"><![CDATA[Omalizumab como adjuvante en el tratamiento de dermatitis severa atópica en niños. Una serie de casos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Durán-Crane]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[Edgardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fundación Universidad Ciencias de la Salud  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de los Andes  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundación Santa Fe de Bogotá  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2019</year>
</pub-date>
<volume>66</volume>
<numero>3</numero>
<fpage>282</fpage>
<lpage>291</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902019000300282&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902019000300282&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902019000300282&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Atopic dermatitis (AD) is a chronic skin disease that affects 5-20% of children. This disease compromises the quality of life. Omalizumab offers a promising role in the treatment of severe atopic dermatitis.  Objective:  To share our experience with the use of omalizumab for treating severe AD in children.  Methods:  A retrospective review of the cases of pediatric patients with severe atopic dermatitis who were treated with omalizumab as an adjuvant therapy in an outside allergy service. Patients under 18 who had been treated for at least 6 months were included.  Results:  19 patients were included. At the beginning of the study, all patients reported a compromise of life quality of 8/10 or more on a analogue scale. A majority of patients had previously received either systemic steroids or other immunosuppressive therapies without obtaining symptom control. At maximum treatment time, the obtained SCORAD scores revealed that the disease in 85.7% of the patients was mild/moderate while, in 14% of the patients, the disease was severe. The Children&#8217;s Dermatological Life Quality Index (CDLQI) was consistent with the SCORAD scores. From the beginning of treatment to the last visit to the doctor&#8217;s office, no patient required systemic steroid therapy.  Conclusions:  Omalizumab appears promising for treating severe atopic dermatitis in pediatric patients. That results shows that omalizubam improves the quality of life, also decreases the severity of the disease and the need for systemic steroid and immunosuppressive therapy, which decreases the side effects that are caused by these medications.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  La dermatitis atópica (EA) es una enfermedad crónica de la piel que afecta de 5 a 20% de los niños. Esta enfermedad compromete la calidad de vida. El omalizumab ofrece un papel prometedor en el tratamiento de la dermatitis atópica severa.  Objetivo: Dar a conocer nuestra experiencia con el uso de omalizumab para la dermatitis atópica severa en niños.  Métodos:  Revisión retrospectiva de los casos de pacientes pediátricos con dermatitis atópica severa tratados con omalizumab como terapia adyuvante en un servicio de consulta externa de alergia. Se incluyeron los pacientes menores de 18 años tratados durante al menos seis meses.  Resultados:  Se incluyeron 19 pacientes. Al inicio del estudio, todos informaron un compromiso de calidad de vida de 8/10 o más en una escala análoga. La mayoría había recibido previamente esteroides sistémicos u tratamiento de inmunosupresión, sin obtener el control de los síntomas. En el tiempo de tratamiento máximo, las puntuaciones SCORAD obtenidas revelaron 85.7% de los pacientes con enfermedad leve-moderada y 14% con enfermedad grave. El Índice de Calidad de Vida Dermatológica Infantil fue consistente con las puntuaciones SCORAD. Desde el comienzo del tratamiento hasta la última visita al consultorio, ningún paciente requirió tratamiento con esteroides sistémicos.  Conclusiones:  Omalizumab parece prometedor para el tratamiento de la dermatitis atópica severa en pacientes pediátricos. Los resultados muestran que omalizumab mejora la calidad de vida, reduce la gravedad de la enfermedad y la necesidad de esteroides sistémicos y terapia inmunosupresora, lo que disminuye los efectos secundarios de estos medicamentos.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Pediatric atopic dermatitis]]></kwd>
<kwd lng="en"><![CDATA[Omalizumab]]></kwd>
<kwd lng="en"><![CDATA[Corticosteroids]]></kwd>
<kwd lng="en"><![CDATA[Adjuvant therapy]]></kwd>
<kwd lng="en"><![CDATA[Clarithromycin]]></kwd>
<kwd lng="es"><![CDATA[Dermatitis atópica pediátrica]]></kwd>
<kwd lng="es"><![CDATA[Omalizumab]]></kwd>
<kwd lng="es"><![CDATA[Corticosteroides]]></kwd>
<kwd lng="es"><![CDATA[Terapia adyuvante]]></kwd>
<kwd lng="es"><![CDATA[Claritromicina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Ulrik]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Kyvik]]></surname>
<given-names><![CDATA[KO]]></given-names>
</name>
<name>
<surname><![CDATA[Hjelmborg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Skadhauge]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Steffensen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importance of genetic factors in the etiology of atopic dermatitis: a twin study]]></article-title>
<source><![CDATA[Allergy Asthma Proc.]]></source>
<year>2007</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>535-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Shobaili]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Alnomair]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Alobead]]></surname>
<given-names><![CDATA[ZA]]></given-names>
</name>
<name>
<surname><![CDATA[Rasheed]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular genetic of atopic dermatitis: an update]]></article-title>
<source><![CDATA[Int J Health Sci (Qassim)]]></source>
<year>2016</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-120</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deckers]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[McLean]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Linssen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mommers]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van Schayck]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Sheikh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies]]></article-title>
<source><![CDATA[PloS One]]></source>
<year>2012</year>
<volume>7</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solé]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mallol]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wandalsen]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<collab>Latin American ISAAC Phase 3 Study Group</collab>
<article-title xml:lang=""><![CDATA[Prevalence of symptoms of eczema in Latin America: results of the International Study of Asthma and Allergies in Childhood (ISAAC) Phase 3]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol]]></source>
<year>2010</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>311-23</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dennis]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Caraballo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[MX]]></given-names>
</name>
<name>
<surname><![CDATA[Rondon]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study]]></article-title>
<source><![CDATA[BMC Pulm Med]]></source>
<year>2012</year>
<volume>12</volume>
<numero>17</numero>
<issue>17</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiebert]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sorensen]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Revicki]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fagan]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Doyle]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atopic dermatitis is associated with a decrement in health-related quality of life]]></article-title>
<source><![CDATA[Int J Dermatol]]></source>
<year>2002</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>151-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Daudén-Tello]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lara-Surinyac]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study]]></article-title>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2013</year>
<volume>104</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-52</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis-Jones]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema]]></article-title>
<source><![CDATA[Int J Clin Pract]]></source>
<year>2006</year>
<volume>60</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>984-92</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bantz]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Atopic March: progression from atopic dermatitis to allergic rhinitis and asthma]]></article-title>
<source><![CDATA[J Clin Cell Immunol]]></source>
<year>2014</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>202</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eichenfield]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Tom]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Krol]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Paller]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Schwarzenberger]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2014</year>
<volume>71</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>116-32</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Breternitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kowatzki]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Langenauer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elsner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fluhr]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation]]></article-title>
<source><![CDATA[Skin Pharmacol Physiol]]></source>
<year>2008</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-45</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sidbury]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Cordoro]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2014</year>
<volume>71</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>327-49</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoare]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Li-Wan]]></surname>
<given-names><![CDATA[Po A]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review of treatments for atopic eczema]]></article-title>
<source><![CDATA[Health Technol Assess]]></source>
<year>2000</year>
<volume>4</volume>
<numero>37</numero>
<issue>37</issue>
<page-range>1-191</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheinkopf]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Rafi]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Do]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Klaustermeyer]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study]]></article-title>
<source><![CDATA[Allergy Asthma Proc]]></source>
<year>2008</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>530-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigo]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neffen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Rodriguez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2011</year>
<volume>139</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>28-35</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Páez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Macías]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Olmos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de Falco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atopic dermatitis guideline. Position paper from the Latin American Society of Allergy, Asthma and Immunology]]></article-title>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2014</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>178-211</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hon]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Kam]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CDLQI, SCORAD and NESS: are they correlated?]]></article-title>
<source><![CDATA[Qual Life Res]]></source>
<year>2006</year>
<volume>15</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1551-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilera-Godoy]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Orbe-Nájera]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
</person-group>
<source><![CDATA[Validación del cuestionario dermatológico de calidad de vida en niños (childrens dermatology life quality index CDLQI). versión en castellano, en pacientes pediátricos con dermatitis atópica, en el centro de la piel Quito - Ecuador]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Pontificia Universidad Católica del Ecuador]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holm]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Agner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sand]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab for atopic dermatitis: case series and a systematic review of the literature]]></article-title>
<source><![CDATA[Int J Dermatol]]></source>
<year>2017</year>
<volume>56</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-26</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>2016</year>
<volume>138</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1719-22</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Cheyney]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Kent]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of recalcitrant atopic dermatitis with omalizumab]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2006</year>
<volume>54</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-72</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lacombe-Barrios]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bégin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Paradis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hatami]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Paradis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Des Roches]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective]]></article-title>
<source><![CDATA[Am Acad Dermatol]]></source>
<year>2013</year>
<volume>69</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>832-4</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iyengar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Hoyte]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Loza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bonaccorso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chiang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Umetsu]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial]]></article-title>
<source><![CDATA[Int Arch Allergy Immunol]]></source>
<year>2013</year>
<volume>162</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>89-93</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zarogoulidis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Papanas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kioumis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chatzaki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maltezos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Zarogoulidis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2012</year>
<volume>68</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>479-503</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hashimoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kaneda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Akashi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nakaike]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clarithromycin inhibits the development of dermatitis in NC/Nga mice]]></article-title>
<source><![CDATA[Chemotherapy]]></source>
<year>2003</year>
<volume>49</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>222-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iveti&#263; Tkal&#269;evi&#263;]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cu&#382;i&#263;]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kramari&#263;]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Parnham]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Erakovi&#263; Haber]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity]]></article-title>
<source><![CDATA[Inflammation]]></source>
<year>2012</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>192-205</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Shaikhly]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ochs]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyper IgE syndromes: clinical and molecular characteristics]]></article-title>
<source><![CDATA[Immunol Cell Biol]]></source>
<year>2018</year>
<volume>97</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>368-79</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez del Pozo]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Contreras-Contreras]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[López-Tiro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Vera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol]]></source>
<year>2011</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>416-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
